Reactive oxygen species x Electron transport chain complex proteins

Primary objective: To evaluate the clinical effectiveness of idebenone tablets (compared with placebo) for the treatment of visual impairment in patients with Leber’s hereditary optic neuropathy (LHON). Clinical effectiveness was evaluated based on the proportion of subjects achieving CRR (i.e., BCVA improvement ≥0.2 logMAR within the visual mark and BCVA ≤1.6 logMAR outside the visual mark compared with baseline) at Week 52. Secondary objective: To evaluate the safety of idebenone in patients with Leber’s hereditary optic neuropathy (LHON).